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SUMMARY
Cryptococcosis is a worldwide disease caused by the etiological agent Cryptococcus neoformans. It affects mainly
immunocompromised humans. It is relatively rare in animals only affecting those that have received prolonged antibiotic therapy.
The propolis is a resin that can present several biological properties, including antibacterial, antifungal and antiviral activities. The
standard strain C. neoformans ATTC 90112 was used to the antifungal evaluation. The tests were realized with propolis ethanol
extract (PEE) G12 in concentrations from 0.1 to 1.6 mg mL-1. The evaluation of MIC and MFC were done according to DUARTE
(2002)5. The inhibitory effect of PEE G12 on the fungal growing was seen at the concentration of 0.2 mg mL-1 and 1.6 mg mL-1 was
considered a fungicidal one.
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INTRODUCTION
With an enlarging immunocompromised population through the
panepidemic of HIV infection and the aggressive use of
immunosuppressant agents such as corticosteroids for cancer, organ
transplantation and other serious medical conditions, cryptococcosis
has become a relatively common infection worldwide as we begin the
new millennium. It is caused by the encapsulated pathogenic yeast
Cryptococcus neoformans8.
According to BERNARDO et al.2, the disease is relatively rare in
animals except for those that were submitted to large antibiotic and
anti-inflammatory therapies. There are some reports of bovine mastitis
and pulmonary infections caused by C. neoformans. COSTA et al.4
found 12% of the lactating cow mastitis caused, mainly, by this yeast.
At the last decades, it has been observed a growth on the interests
in alternative medicines and natural therapies, especially, those
involving substances with antimicrobial properties like propolis among
others14.
The propolis is a complex resinous bee product with a physical
appearance that varies widely, depending on many factors. It is collected
by bees - Apis mellifera - from the buds or other parts of the trees. It is
known for its antibacterial, antifungal and healing properties12. As the
most important chemical weapon of bees against pathogenic
microorganisms, propolis has been used as a medicine by human being
since ages ago for treatment of wounds, burns, sore throats and stomach
ulcers. For this reason, propolis has become the subject of intense
pharmacological and chemical studies for the last 30 years1.
The propolis composition is extremely complex. Some factors as
the vegetal ecology from the region where propolis was collected and
even the genetic variability in queen bee can influence the chemical
composition of this resinous material14.
Due to the wide variability of its chemical compositions depending
on its origin, the chemical standardization is extremely difficult3.
Several biological and therapeutic activities have been associated with
the presence of flavonoids, aromatic acids and esters. In the Brazilian
samples other classes of bioactive components, instead of flavonoids,
have been described, such as prenylated phenolic acids and specific
terpenoids. It is also known that the biological activities of a sample
depend on the extraction methodology employed.
The Brazilian propolis has been classified into 12 groups based on
physicochemical characteristics: five in the Southern Brazil group
(group 3), one in the Southeastern Brazil group (group 12) and six in
the Northeastern Brazil group (group 6)15.
Numerous studies carried out with combined efforts of
phytochemists and pharmacologists, led on recent years to the idea
that different propolis samples could be completely different in their
chemistry and biological activity1.
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The propolis is used traditionally in folk medicine mainly because
its antibacterial effect. Other properties, as antifungal, antiviral, anti-
inflammatory and immuno-stimulating have also been described to
this resin3,10.
By this way, with the intention to prevent some undesirable effects
arisen from the use of antibiotic and antifungal drugs and also to obtain
an alternative and efficient substance, efficient against pathogenic yeast
growth. The goal of this work was to evaluate the propolis from group
12 (G12) that according to FERNANDES et al.6 has showed the best
antifungal activity in susceptibility evaluations. It was evaluated the
“in vitro” antifungal activity of propolis G12 ethanol extract (PEE) on
Cryptococcus neoformans.
MATERIAL AND METHODS
The antifungal activity of the propolis G12, so named “green
propolis”, was evaluated in the concentration of 0.1; 0.2; 0.4; 0.8; 1.2
and 1.6 mg mL-1 of propolis in a 80% ethanol solution according to
IKEGAKI9.
The susceptibility test employed the C. neoformans standard strain
ATCC 90112. The strain was subcultured on Sabouraud dextrose agar
at 25 °C during 48 h. The inoculum was diluted in 0.9% NaCl solution
to the concentration of 2 .108 UFC mL-1.
The determination of Minimum Inhibitory Concentration (MIC)
was realized according to the methodology proposed by DUARTE5. A
volume of 0.5 mL from the standardized inoculum was added to 49.5
mL Sabouraud broth and the resulting colonies were counted.
The control was eight tubes with Sabouraud broth inoculated with
C. neoformans ATCC90112, ATCC90112 and ethanol 80%, ATCC90112
in each one of the 6 PEE concentrations respectively. The medium was
agitated and incubated during 48 h at 28 oC. The growth evaluation
was done by absorbance reading.
The Minimum Fungicidal Concentration (CFM) and MIC were
determined according to DUARTE5 across the colony counting on
Sabouraud agar dishes. The inoculum was all the suspension that
presented an absorbance result minor or equal than 0.05 at 660 nm.
The volume of 50 µL was added on to the agar and spread with a swab.
The incubation was at 28 °C during 48 h. The MFC was defined as the
lowest PEE concentration in which there wasn’t cellular growing on to
the agar surface.
RESULTS AND DISCUSSION
According to the methodology, the MIC was observed in the
concentration of 0.2 mg mL-1 to the standard strain C. neoformans ATCC
90112 (Table 1). Other researches have shown MIC and MFC at higher
concentrations of the PEE G12 than ours6,13. FERNANDES Jr. et al.7
verified fungistatic effect at the concentration of 3.8 mg.mL-1 to Candida
albicans and 2.1 mg.mL-1 to C. tropicalis.
The MFC was observed at the concentration of 1.6 mg.mL-1 (Table
1). To Malassezia pachydermatis, a yeast that is frequently isolated
from otitis externa in dogs, LILENBAUM & BARBOSA11 used propolis
extract from apiary Itamel in Itaboraí, Rio de Janeiro State and observed
fungicidal effect only into the concentration of 2.4 mg mL-1. OTA et
al.13 found propolis fungicidal activity inside a range from 9 to 10 mg
mL-1 in 65% of Candida sp. strains.
According to SALATINO et al.17 many compounds may be involved
in the biological activity of G12 propolis. Prenylated cinnamic acid-
derived compounds, such as 3,5-diprenyl-4-hydroxycinnamic acid
(Artepillin C) has shown to possess antimicrobial activity. Mono and
sesquiterpenes are frequently detected in propolis G12, probably
contributing to the antimicrobial activity.
Beyond that compounds, the propolis G12 has flavonoids in its
composition. These phenolic compounds are considered as one of the
mainly responsible for its antimicrobial activity1,15. QUIROGA et al.16
demonstrated that pinocembrin and galangin were partially responsible
to the toxic activity against several strains of phytopathogenic fungi.
The minimal inhibitory concentration values for pinocembrin and
galangin were between 14-40 µg mL-1.
The beneficial effects of the propolis have been mentioned since
ages ago. According to our results, the analyzed standard strain was
shown to be sensitive to the PEE G12 in almost all the evaluated
concentrations. Cryptococcosis is until now a worldwide mycose that
has been characterized by the development of resistance among many
strains after antifungal therapies. So, alternative therapies can be an
option since more “in vitro” studies may be done and related to some
established parameters of the “in vivo” efficacy.
RESUMO
Avaliação da atividade antifúngica do extrato etanólico de
própolis G12 sobre Cryptococcus neoformans
Criptococose, doença cosmopolita, causada pelo agente etiológico
Cryptococcus neoformans, está associada, principalmente, a indivíduos
imunocomprometidos. O acometimento de animais é relativamente
raro, exceto, nos casos associados à prolongada antibioticoterapia. A
própolis é uma resina que pode apresentar diversas propriedades
biológicas, incluindo atividades antibacterianas, antifúngicas e
antivirais. Amostra padrão de C. neoformans foi utilizada no teste de
atividade antifúngica do extrato etanólico de própolis (EEP) G12 nas
Table 1
The results of MIC and MFC of PEE G12 to the Standard Strain Cryptococcus
neoformans ATCC 90112
PEE G12 concentrations MIC MFC
(mg.mL-1)
0.1 - -
0.2 + -
0.4 + -
0.8 + -
1.2 + -
1.6 + +
The signs + and – indicate positive and negative results respectively.
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concentrações de 0,1 a 1,6 mg.mL-1. As avaliações da Concentração
Inibitória Mínima (CIM) e Concentração Fungicida Mínima (CFM)
foram realizadas conforme DUARTE5. O efeito inibitório do EEP G12
sobre o crescimento fúngico foi observado na concentração de 0,2
mg.mL-1. A concentração de 1,6 mg.mL-1 foi considerada fungicida.
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